Landau, Nathaniel R.

Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection

Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., & Landau, N. R. (1996) · Cell

HIV Research and TreatmentChemokine receptors and signaling

Cited by 3,074

Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes

Connor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995) · Virology

HIV Research and TreatmentHIV/AIDS drug development and treatment

Cited by 1,253

SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates

Lahouassa, H., Daddacha, W., Hofmann, H., Ayinde, D., Logue, E. C., Dragin, L., Bloch, N., Maudet, C., Bertrand, M., Gramberg, T., et al. (2012) · Nature Immunology

HIV Research and TreatmentVirus-based gene therapy research

Cited by 852

CCR5 is a receptor for Staphylococcus aureus leukotoxin ED

Alonzo III, F., Kozhaya, L., Rawlings, S. A., Reyes-Robles, T., DuMont, A. L., Myszka, D. G., Landau, N. R., Unutmaz, D., & Torres, V. J. (2013) · Nature

Antimicrobial Resistance in StaphylococcusChemokine receptors and signaling

Cited by 291

HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1

Schröfelbauer, B., Hakata, Y., & Landau, N. R. (2007) · Proceedings of the National Academy of Sciences

HIV Research and TreatmentDNA Repair Mechanisms

Cited by 187

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

Tada, T., Dcosta, B. M., Samanovic-Golden, M., Herati, R. S., Cornelius, A., Mulligan, M. J., & Landau, N. R. (2021) · mBio

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 153

The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies

Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., & Landau, N. R. (2021) · iScience

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 101

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera

Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., & Landau, N. R. (2021) · iScience

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 101

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies

Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R., & Tada, T. (2021) · mBio

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 68

Interactions with DCAF1 and DDB1 in the CRL4 E3 ubiquitin ligase are required for Vpr-mediated G2 arrest

Hakata, Y., Miyazawa, M., & Landau, N. R. (2014) · Virology Journal

HIV Research and TreatmentUbiquitin and proteasome pathways

Cited by 13